Gallium-67 scintigraphy in the management: Hodgkin's disease and non- Hodgkin's lymphoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 14, Issue 4, 1999, Pages 251-262

  Rehm, Patrice K ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALLIUM 67; TECHNETIUM 99M; TETROFOSMIN TC 99M;

CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; DIAGNOSTIC IMAGING; DRUG EXCRETION; DRUG MONITORING; DRUG RESPONSE; DRUG UPTAKE; HODGKIN DISEASE; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCINTIGRAPHY; TISSUE DISTRIBUTION;

EID: 0032803242     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1999.14.251     Document Type: Review

References (68)

1. McLaughlin AF, Magee MA, Greenough R, et al. Current role of gallium scanning in the management of lymphoma. Eur J Nucl Med 1990;16:755-771.
2. Silberstein EB, Fernandez-Ulloa M, Hall J. Are oral cathartics of value in optimizing the gallium scan? Concise communication. J Nucl Med 1981;22:424-7.
3. Noujaim AA, Turner CJ, Scott J. The effect of amphotericin B on 67Ga biodistribution. Int J Nucl Med Biol 1985;12:70-2.
4. Akansel G, Liu Y, Chitambar CR, et al. Effect of gallium nitrate therapy on Ga-67 scintigraphic detection of lymphoma: case report. Clin Nucl Med 1997;22:21-4.
5. Hattner RS, White DL. Gallium-67 / stable gadolinium antagonism: MRI contrast agent markedly alters the normal biodistribution of Ga-67. J Nucl Med 1990; 31:1844-1846.
6. Engelstad B, Luk SS, Hattner RS. Altered 67Ga citrate distribution in patients with multiple red blood cell transfusions. AJR 1982;139:755-759.
7. Bekerman C, Pavel DG, Bitran J, Ryo UY, Pinsky S. The effects of inadvertent administration of antineo-plastic agents prior to Ga-67 injection: concise communication. J Nucl Med 1984;25:430-5.
8. Personal communication. Front D. Rambam Medical Center, Bat Galim, Haifa, Israel 35254.
9. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392.
10. Hagemsister FB. Hodgkin's disease: the next decade. Leukemia and Lymphoma 1996;21:53-61.
11. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
12. DeNardo GL, O'Donnell RT, Oldham RK and DeNardo SJ. A revolution in the treatment of non-Hodgkin's Lymphoma. Cancer Biotherapy and Radiopharmaceuticals 1998;13:213-23.
13. Front D, Bar-Shalom R, Israel O. Role of Gallium and other radiopharmaceuticals in the management of patients with lymphoma. in Nuclear Medicine Annual, Freeman LM (ed). Philadelphia, Lippincott Raven Publishers, Inc. 1998. pp 247-264.
14. Anderson KD, Leonard RCF, Canellos GP. High-dose gallium imaging in lymphoma. Am J Med 1983;75:327-331.
15. Sandrock D, Lastoria S, Magrath IT, et al. The role of gallium-67 tumour scintigraphy in patients with small, non-cleaved cell lymphoma. Eur J Nucl Med 1993;20:119-122.
16. Waxman AD, Eller D, Ashook G, et al. Comparison of gallium-67-citrate and thallium-201 scintigraphy in peripheral and intrathoracic lymphoma. J Nucl Med 1996;37:46-50.
17. Ben-Haim S, Bar-Shalom R, Israel O, et al. Utility of gallium-67 scintigraphy in low-grade non-Hodgkin's lymphoma. J Clin Oncol 1996;14:1936-42.
18. Hussain R, Christie DR, Gebski V, Barton MB, Gruenewald SM. The role of the gallium scan in primary extranodal lymphoma. J Nucl Med 1998;39:95-8.
19. Jochelson MS, Herman TS, Stomper PC, Mauch PM, Kaplan WD. Planning mantle radiation therapy in patients with Hodgkin disease: role of gallium-67 scintigraphy. AJR Am J Roentgenol 1988;15:1229-31.
20. Front D, Israel O. The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. Semin Nucl Med 1995;25:60-71.
21. Setoain FJ, Pons F, Herranz R, et. al. 67Ga scintigraphy for the evaluation of recurrences and residual masses in patients with lymphoma. Nucl Med Commun 1997;18:405-11.
22. Kostakoglu L, Yeh SD, Portlock C, et al. Validation of gallium-67 citrate single photon emission computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum. J Nucl Med 1992;33:345-350.
23. Hill M, Cunningham D, MacVicar D, Roldan A, Husband J, McCready R, Mansi J, Milan S, Hickish T. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J Clin Oncol 1993;11:2273-8.
24. Zinzani PL, Zompatori M, Bendandi M, et al. Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1996;22:131-5.
25. Devizzi L, Maffioli L, Bonfante V, et al. Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease. Ann Oncol 1997;8:53-6.
26. Gasparini MD, Balzarini L, Castellani MR, et al. Current role of gallium scan and magnetic resonance imaging in the management of mediastinal Hodgkin lymphoma. Cancer 1993, 72:577-82.
27. Israel O, Front D, Lam M, et. al. Gallium 67 imaging in monitoring lymphoma response to treatment. Cancer 1988;61:2439-43.
28. Weeks JC, Yeap BY, Canellos GP, Shipp MA. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 1991;9:1196-203.
29. Front D, Bar-Shalom R, Epelbaum R, et al. Early detection of lymphoma recurrence with gallium-67 scintigraphy. J Nucl Med 1993;34:2101-4.
30. Cooper DL, Caride VJ, Zloty M, Germino J, Farber LR, Hoffer PB. Gallium scintigraphy in patients with mediastinal Hodgkin's disease treated with chemotherapy. J Clin Oncol 1993;11:1092-8.
31. Israel O, Front D, Lam M, et. al. Gallium 67 imaging in monitoring lymphoma response to treatment. Cancer 1988 15;61:2439-43.
32. Gallamini A, Biggi A, Fruttero A, et. at. Revisiting the prognostic role of gallium scintigraphy in low-grade non-Hodgkin's lymphoma. Eur J Nucl Med 1997;24:1499-506.
33. Front D, Ben-Haim S, Israel O, et al. Lymphoma: Predictive value of Ga-67 scintigraphy after treatment. Radiology 1992;182:359-363.
34. Wylie BR, Southee AE, Joshua DE, et al. Gallium scanning in the management of mediastinal Hodgkin's disease. Eur J Haematol 1989;42:344-7.
35. Front D, Israel O, Epelbaum R, et al. Ga-67 SPECT before and after treatment of lymphoma. Radiology 1990;175:515-9.
36. Kirn D, Mauch P, Shaffer K, et al. Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients. J Clin Oncol 1993, 11:1336-43.
37. King SC, Reiman RJ, Prosnitz LR. Prognostic importance of restaging gallium scintigraphy following induction chemotherapy for advanced Hodgkin's disease. J Clin Oncol 1994;12:306-11.
38. Kaplan WD, Jochelson MS, Herman TS, et al. Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol 1990;8:1966-70.
39. Ben-Haim S, Bar-Shalom R, Israel O, et al. Liver involvement in lymphoma: role of gallium-67 scintigraphy [clinical conference]. J Nucl Med 1995;36:900-4.
40. Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA. Early restaging gallium scintigraphy predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997;15:1631-7.
41. Vose JM, Bierman PJ, Anderson JR, et. al. Singlephoton emission computed tomography gallium imaging versus computed tomography: predictive value in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1996;14:2473-9.
42. Hagemeister FB, Purugganan R, Podoloff DA, et al. The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy. Ann Oncol 1994;5:59-63.
43. Salloum E, Brandt DS, Caride VJ, et al. Gallium scintigraphy in the management of patients with Hodgkin's disease: a study of 101 patients. J Clin Oncol 1997;15:518-27.
44. Mouratidis B, Gilday DL, Ash JM. Comparison of bone and 67Ga scintigraphy in the initial diagnosis of bone involvement in children with malignant lymphoma. Nucl Med Commun 1994;15:144-7.
45. Bar-Shalom R, Israel O, Epelbaum, R, et al. Gallium-67 scintigraphy in lymphoma with bone involvement. J Nucl Med 1995;36:446-450.
46. Roach PJ, Janicek MJ, Kaplan WD. Bone lymphoma. Comparison of T1-201 and Ga-67 citrate scintigraphy in assessment of treatment response. Clin Nucl Med 1996;21:689-94.
47. Moon TY, Kim EE, Kim YC, Chung JK, Kim BS, Lee SH, Kim KI, Podoloff DA. Comparison of nuclear bone and gallium scintigraphy in the therapeutic evaluation of bone lymphoma. Clin Nucl Med 1995;20:721-4.
48. Front D, Bar-Shalom R, Iosilevsky G, et al. Ga-67 scintigraphy with a dual-head camera. Clin Nucl Med 1995;20:542-8.
49. Tumeh SS, Rosenthal DS, Kaplan WD, et al. Lymphoma: evaluation with Ga-67 SPECT. Radiology 1987;164:111-114.
50. Front D, Israel O, Epelbaum R, et al. Ga-67 SPECT before and after treatment of lymphoma. Radiology 1990;175:515-9.
51. Tan TX, Gelfand MJ. Ga-67 scintigraphy in pediatric patients. Comparison of extended SPECT of the chest and abdomen with planar imaging. Clin Nucl Med 1996;21:717-9.
52. Keyes JW Jr. Three-dimensional display of SPECT images: advantages and problems. J Nucl Med 1990;31:1428-30.
53. Peylan-Ramu N, Haddy TB, Jones E, Horvath K, Adde MA, Magrath IT. High frequency of benign mediastinal uptake of gallium-67 after completion of chemotherapy in children with high-grade non-Hodgkin's lymphoma. J Clin Oncol 1989;7:1800-6.
54. Champion PE, Groshar D, Hooper IIR, et al. Does gallium uptake in the pulmonary hila predict involvement by non-Hodgkin' s lymphoma? Nuc Med Commun 1992;13:730-737.
55. Bar-Shalom R; Israel O; Haim N, et al. Diffuse lung uptake of Ga-67 after treatment of lymphoma: is it of clinical importance? Radiology 1996;199:473-6.
56. Ziegels P, Nocaudie M, Huglo D, et al. Comparison of technetium-99m methoxyisobutylisonitrile and gallium-67 citrate scanning the assessment of lymphomas. Eur J Nucl Med 1995;22:126-131.
57. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Research 1993;53:977-984.
58. Dimitrakopoulou-Strauss A, Strauss LS, Goldschmidt H, Lorenz WJ, Maier-Borst W, van Kaick G. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1995;22:434-442.
59. Ballinger JR, Bannerman J, Boxen I, Firby P, Hartman NG, Moore MJ. Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells. J Nucl Med 1996;37:1578-1582.
60. Kapucu LO, Akyuz C, Vural G, et al. Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi. J Nucl Med 1997;38:243-247.
61. Lipp RW, Silly H, Ranner G, et al. Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy. J Nucl Med 1995;36:13-18.
62. Cerulus G, Leonard J-P. A comparison of 111 Inoctreotide and 67Ga scintigraphy in malignant lymphoma. Nucl Med Commun 1997;18:616-622.
63. Hoh CK, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997;38:343-8.
64. Okada J, Yoshikawa K, Imazeki K, et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med ;32:686-91.
65. Rosenfeld SS, Hoffman JM, Coleman RE, Glantz MJ, Hanson MW, Schold SC. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. J Nucl Med 1992,33(4):532-6.
66. Dimitrakopoulou-Strauss A, Strauss LS, Goldschmidt H, Lorenz WJ, Maier-Borst W, van Kaick G. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1995;22:434-42.
67. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997;203:795-800.
68. Hoekstra OS, Ossenkoppele GJ, Golding R, et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 1993;34:1706-10.